Online citations, reference lists, and bibliographies.
← Back to Search

Conversion Surgery For Locally Advanced Malignant Pleural Mesothelioma

Y. Terada, M. Isaka, H. Murakami, Takuya Kawata, H. Konno, H. Kojima, Tetsuya Mizuno, Y. Ohde
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Two women in their sixties were diagnosed with inoperable locally advanced epithelioid malignant pleural mesothelioma, c-stage IIIB. Post-chemotherapy, the tumors down-staged to yc-stage IA, and pleurectomy/decortication were performed. The pathological diagnoses were p-stages II and IA. One patient had tumor recurrence 6 months after surgery; she is currently undergoing fourth-line chemotherapy and is alive 30 months postoperatively. The second patient had tumor recurrence 4 months after surgery and died 2 months later. Conversion surgery for advanced malignant mesothelioma does not improve progression-free survival but might have a chance to extend overall survival in selected patients without deteriorating performance status.
This paper references
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
J. Friedberg (2017)
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
A phase II study of nivolumab: a multicenter, open-label, single General Thoracic and Cardiovascular Surgery 1 3 arm study in malignant pleural mesothelioma (MERIT)
Y Goto (2017)
Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma
S. Boeluekbas (2012)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Longterm survival after lung-sparing total pleurectomy for locally advanced (international mesothelioma interest group stage T3– T4) non-sarcomatoid malignant pleural mesothelioma
A Nakas (2012)
MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
Y. Goto (2017)
A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT).
K. Aoe (2018)
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)

Semantic Scholar Logo Some data provided by SemanticScholar